InSite Vision

Executive Summary

Plans to file amended NDA for MethaSite (extended-release fluorometholone eyedrops) in first half of 1994, company reports in Aug. 27 prospectus for an initial public offering of 3 mil. shares. MethaSite was designated approvable by FDA in March 1990 for control of mild-to-moderate inflammation in the anterior segment of the eye. The Alameda, Calif. company subsequently conducted a second Phase III trial using "the 'blow, fill, seal' manufacturing process to be used for the commercial production of MethaSite," the prospectus states. Morgan Stanley and Robertson Stephens are underwriting the offering.